[Brief Introduction of Seminar]

In the pharmaceutical industry, the utilization of AI technologies during new drug development stages is steadily increasing to achieve time and cost efficiency. Alongside growing interest and application of various solutions such as DeepMind’s AlphaFold and NVIDIA’s BioNeMo for streamlining drug development processes, applying AI to pharmaceutical manufacturing and production is also becoming a crucial topic to enhance quality standardization and improve production efficiency. This presentation aims to explore the implications of applying AI in pharmaceutical production by introducing optimization cases based on AI technologies and data-driven approaches across diverse industries. 

[Brief Introduction of Speaker]

Mr. Hanseung Ko is currently responsible for AI project business development at Machinaraks, a specialized industrial AI startup. He majored in Business Administration at Yonsei University and has over 10 years of experience at EY Consulting and Deloitte Consulting, where he developed strategies, process innovations, and digital transformation use cases to solve various business challenges. At Machinaraks, he is actively leading AI transformation initiatives with multiple manufacturing clients to address on-site operational issues.

​

[Brief Introduction of Seminar]

Medical data is not merely recorded information but a key asset for advancing personalized predictive healthcare. This presentation will introduce approaches for integrating and analyzing medical data using AI and digital twin technologies, and demonstrate the feasibility and applications of clinical decision support systems based on these methods. Focusing on the implementation of a ‘DNA-based Human Digital Twin’—which enables personalized prescriptions such as adverse reaction prediction, optimal dosage determination, and improved transplant success rates through genomic information—the talk will discuss practical clinical applications and industrial value. Furthermore, it will present strategic frameworks for monetizing medical data across diverse industry stakeholders, including hospitals, pharmaceutical companies, and insurers (e.g., PAaaS, clinical trial optimization, IoMT), aiming to contribute to the formulation of data-driven future strategies in Korea’s biohealth industry. 

[Brief Introduction of Speaker]

Professor Sajung Yoon holds a Ph.D. from the John A. Burns School of Medicine and an M.B.A. from Johns Hopkins University. He is currently an adjunct professor in the Department of Biomedical Informatics at Johns Hopkins University. He also serves as CEO of the digital healthcare startup Predictive AI, which is developing digital twins based on genomic analysis and AI-driven personalized preventive healthcare platforms. Previously, he conducted gene transfer research as a research fellow at the U.S. National Institutes of Health (NIH) and has contributed to convergence research and commercialization in the biohealth and medical informatics fields. He has received numerous awards, including the Venture Business Association President’s Award, the 4IR Awards Grand Prize in AI/Biohealth, and was named CEO of the Year in Medical IT. 

​

[Brief Introduction of Seminar]

Artificial intelligence (AI) drug development has so far been concentrated in the early stages, increasing the need for AI strategies that bridge the gap between preclinical and clinical trials to improve ultimate success rates. This presentation will explore how AI technologies are being applied in preclinical and clinical phases through real-world case studies, seeking innovative approaches to the drug development process. Focusing on AI applications such as preclinical toxicity prediction, biomarker discovery, and patient stratification, it will analyze the methods and effectiveness at each stage and offer actionable insights for implementation in research settings.

​ 

[Brief Introduction of Speaker]

​Dr. Jinseon Kwon, Director of the Innovation New Drug Research and Development Center at Pharos I Bio, holds a Ph.D. in Pharmaceutical Biotechnology from Korea University and is an expert in medicinal synthesis and innovative drug discovery. Previously, she served as the leader of the Innovative Drug Development Division at IlDong Pharmaceutical’s Central Research Institute, successfully leading multiple new drug development projects including antibiotics, anticancer agents, anticoagulants, immunotherapy drugs, and treatments for dry eye syndrome. Notably, she achieved a licensing milestone by out-licensing a preclinical candidate for an immunotherapy drug. Currently, she oversees new drug pipeline development at Pharos I Bio, leveraging her extensive experience and expertise in synthetic drug development.​

[Brief Introduction of Seminar]

New drug development typically requires over 10 years and costs billions to trillions of won, with clinical success rates remaining low. Particularly, failure rates are extremely high in the preclinical stage, and many domestic new drug pipelines remain in early phases. Consequently, early-stage exploration and optimization strategies utilizing AI-based predictive technologies are essential. The demand for precise target-based drug discovery using protein 3D structures continues to dominate and is on the rise. This presentation will introduce how protein structure-based AI platforms can shorten and streamline traditional drug development processes, highlighting the role of the Pharmaco-Net platform through case studies involving collaborative research and technology export with domestic and international institutions. Additionally, it will present AI utilization strategies across the entire global value chain (target identification, compound optimization, clinical candidate selection) and directions for public-private data collaboration. 

[Brief Introduction of Speaker]

​Dr. Youngbin Park earned his Ph.D. from Seoul National University and worked as a researcher in the Virus Section 2 at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan. During his tenure, he conducted diverse research including antiviral drug development, X-ray crystallography of protein 3D structures, viral infection mechanisms, and vaccine validation. He continued his postdoctoral research at Baylor College of Medicine in the United States, which provided momentum for entrepreneurship. Dr. Park co-founded Calici, a company based in both the U.S. and Korea, alongside protein structure and bioinformatics expert Dr. Jaemoon Choi. Together, they are leading the development and operation of Pharmaco-Net (pharmaco-net.org/), a protein structure-based AI platform for drug discovery and functional substance development.​

[Brief Introduction of Seminar]

The global biohealth industry is rapidly undergoing innovation and restructuring across the entire value chain, driven by AI and big data technologies. In areas such as precision medicine, personalized treatment, and disease prediction, real-time data processing and advanced privacy protection technologies are emerging as new competitive advantages, prompting fundamental changes in the ways data is collected and utilized. This presentation will focus on an on-device AI-based MyData platform to propose a paradigm shift in data collection and utilization within the biohealth value chain. In particular, from the perspective of balancing privacy protection and data use within the global regulatory environment, it will explore the strategic importance and scalability of on-device technology, providing practical insights for establishing global strategies in the domestic and international biohealth industries.

​ 

[Brief Introduction of Speaker]

Mr. Jaeyoung Lee graduated from the Department of Electrical and Computer Engineering at Seoul National University and conducted blockchain research while pursuing his Master’s degree at Hanyang University. He is currently an adjunct professor in the AI Technology Management program at Kyung Hee University’s Graduate School of Techno Management. Previously, he served as a senior researcher in the Security Team at Samsung Electronics, specializing in software security and personal data protection. He holds certifications as a Certified Information Systems Security Professional (CISSP), Certified Information Privacy Professional/Europe (CIPP/E), and Certified Ethical Hacker (CEH). He has been awarded honors by the Ministry of Science and ICT as well as the Ministry of SMEs and Startups. Additionally, he serves as an executive member of the Korean Institute of Information Scientists and Engineers (KIPS) and as a Board Director of the MyData Global Association.​

[Brief Introduction of Seminar]

The pharmaceutical and bio industries are among the most prominent sectors globally. Since the worldwide spread of COVID-19 starting in 2019, the importance of the healthcare industry has been increasingly recognized. Health-related concerns arising from the pandemic and the aging populations of many countries are rapidly growing. In the pharmaceutical and bio industries, it is crucial to develop medicines that meet societal needs ahead of others. Currently, AI and big data are key technologies accelerating research planning and business development, with their applications expanding worldwide. In this context, we present an analysis focused on global new drug development trends utilizing AI and big data, and introduce the methodologies employed.

​ 

[Brief Introduction of Speaker]

​Consultant Hyojin Park holds a Bachelor’s degree in Psychology from Indiana University Bloomington and a Ph.D. in Medical Science from Yonsei University. She has worked as a Senior Consultant at the global firm Clarivate, participating in consulting projects across the pharmaceutical and bio industries. Currently, she is responsible for consulting and data solution services in the pharmaceutical and bio sectors for domestic and international companies and government agencies at GlobalData. Since 2021, she has been presenting pharmaceutical and bio market forecasts based on data-driven analysis at major conferences and events organized by the Korea Drug Development Funders Association.​

[Brief Introduction of Seminar]

Prof. Abdullah Al-Mohizea welcomes sharing actionable insights and technical perspectives that support Korean pharmaceutical companies in expanding into the GCC region. His session will explore:

- SFDA registration pathways and regulatory harmonization 

- Fast-track strategies for product approval 

- Regional compliance and technical readiness requirements​ 

[Brief Introduction of Speaker]

Prof. Abdullah Al-Mohizea has over 20 years of experience in Academia, the Regulatory and Pharmaceutical industry. He holds a B.S. in Pharmaceutical Sciences from King Saud University, an MBA (total quality management), an MSc in finance from Leicester University, and a Ph.D. in Pharmaceutical Sciences from University of Pittsburgh. 

Prof. Al-Mohizea is the CEO of Creativity Ocean consultancy and professor at the College of Pharmacy, King Saud University, and a former member of the industrial council, former vice president for the National Association of Pharmaceutical manufacturing companies, and former vice president for the Saudi Pharmaceutical Industry Association. He served previously as the General Manager of Tabuk Pharmaceutical Manufacturing Company and executive director of the product evaluation and standard setting administration at the SFDA, and he is a previous advisor with the World Health Organization (WHO) prequalification program, a previous member of the expert committee for the physical analysis with the United State Pharmacopeia (USP), Gulf Cooperation Council (GCC) and the SFDA registration committees.

​